Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Gel-Based Proteomics of Clinical Samples Identifies Potential Serological Biomarkers for Early Detection of Colorectal Cancer.

Thorsen SF, Gromova I, Christensen IJ, Fredriksson S, Andersen CL, Nielsen HJ, Stenvang J, Moreira JMA.

Int J Mol Sci. 2019 Dec 2;20(23). pii: E6082. doi: 10.3390/ijms20236082.

2.

Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study.

Tesauro C, Simonsen AK, Andersen MB, Petersen KW, Kristoffersen EL, Algreen L, Hansen NY, Andersen AB, Jakobsen AK, Stougaard M, Gromov P, Knudsen BR, Gromova I.

BMC Cancer. 2019 Nov 29;19(1):1158. doi: 10.1186/s12885-019-6371-0.

3.

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.

Gogola E, Duarte AA, de Ruiter JR, Wiegant WW, Schmid JA, de Bruijn R, James DI, Llobet SG, Vis DJ, Annunziato S, van den Broek B, Barazas M, Kersbergen A, van de Ven M, Tarsounas M, Ogilvie DJ, van Vugt M, Wessels LFA, Bartkova J, Gromova I, Andújar-Sánchez M, Bartek J, Lopes M, van Attikum H, Borst P, Jonkers J, Rottenberg S.

Cancer Cell. 2019 Jun 10;35(6):950-952. doi: 10.1016/j.ccell.2019.05.012. No abstract available.

4.

Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics.

Jabeen S, Espinoza JA, Torland LA, Zucknick M, Kumar S, Haakensen VD, Lüders T, Engebraaten O, Børresen-Dale AL, Kyte JA, Gromov P, Naume B, Kristensen V, Gromova I, Tekpli X.

Oncoimmunology. 2018 Nov 5;8(2):e1537691. doi: 10.1080/2162402X.2018.1537691. eCollection 2019.

5.

Release of transcriptional repression via ErbB2-induced, SUMO-directed phosphorylation of myeloid zinc finger-1 serine 27 activates lysosome redistribution and invasion.

Brix DM, Tvingsholm SA, Hansen MB, Clemmensen KB, Ohman T, Siino V, Lambrughi M, Hansen K, Puustinen P, Gromova I, James P, Papaleo E, Varjosalo M, Moreira J, Jäättelä M, Kallunki T.

Oncogene. 2019 Apr;38(17):3170-3184. doi: 10.1038/s41388-018-0653-x. Epub 2019 Jan 8.

6.

Aminoethane Sulfonic Acid Magnesium Salt Inhibits Ca2+ Entry Through NMDA Receptor Ion Channel In Vitro.

Turovsky EA, Blinova EV, Semeleva EV, Zinchenko VP, Astashev ME, Blinov DS, Skachilova SY, Geras'kina MM, Lebedev AB, Gromova IA.

Bull Exp Biol Med. 2018 Nov;166(1):39-42. doi: 10.1007/s10517-018-4284-6. Epub 2018 Nov 12.

PMID:
30417298
7.

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.

Gogola E, Duarte AA, de Ruiter JR, Wiegant WW, Schmid JA, de Bruijn R, James DI, Guerrero Llobet S, Vis DJ, Annunziato S, van den Broek B, Barazas M, Kersbergen A, van de Ven M, Tarsounas M, Ogilvie DJ, van Vugt M, Wessels LFA, Bartkova J, Gromova I, Andújar-Sánchez M, Bartek J, Lopes M, van Attikum H, Borst P, Jonkers J, Rottenberg S.

Cancer Cell. 2018 Jun 11;33(6):1078-1093.e12. doi: 10.1016/j.ccell.2018.05.008. Erratum in: Cancer Cell. 2019 Jun 10;35(6):950-952.

8.

N-glycan signatures identified in tumor interstitial fluid and serum of breast cancer patients: association with tumor biology and clinical outcome.

Terkelsen T, Haakensen VD, Saldova R, Gromov P, Hansen MK, Stöckmann H, Lingjaerde OC, Børresen-Dale AL, Papaleo E, Helland Å, Rudd PM, Gromova I.

Mol Oncol. 2018 Jun;12(6):972-990. doi: 10.1002/1878-0261.12312. Epub 2018 May 14.

9.

Let-7 microRNA controls invasion-promoting lysosomal changes via the oncogenic transcription factor myeloid zinc finger-1.

Tvingsholm SA, Hansen MB, Clemmensen KKB, Brix DM, Rafn B, Frankel LB, Louhimo R, Moreira J, Hautaniemi S, Gromova I, Jäättelä M, Kallunki T.

Oncogenesis. 2018 Feb 3;7(2):14. doi: 10.1038/s41389-017-0014-6.

10.

Identification of BLCAP as a novel STAT3 interaction partner in bladder cancer.

Gromova I, Svensson S, Gromov P, Moreira JMA.

PLoS One. 2017 Nov 30;12(11):e0188827. doi: 10.1371/journal.pone.0188827. eCollection 2017.

11.

Gaining insights into cancer biology through exploration of the cancer secretome using proteomic and bioinformatic tools.

Papaleo E, Gromova I, Gromov P.

Expert Rev Proteomics. 2017 Nov;14(11):1021-1035. doi: 10.1080/14789450.2017.1387053. Epub 2017 Oct 6. Review.

PMID:
28967788
12.

Profiling of microRNAs in tumor interstitial fluid of breast tumors - a novel resource to identify biomarkers for prognostic classification and detection of cancer.

Halvorsen AR, Helland Å, Gromov P, Wielenga VT, Talman MM, Brunner N, Sandhu V, Børresen-Dale AL, Gromova I, Haakensen VD.

Mol Oncol. 2017 Feb;11(2):220-234. doi: 10.1002/1878-0261.12025. Epub 2016 Dec 12.

13.

Cytokine profiling of tumor interstitial fluid of the breast and its relationship with lymphocyte infiltration and clinicopathological characteristics.

Espinoza JA, Jabeen S, Batra R, Papaleo E, Haakensen V, Timmermans Wielenga V, Møller Talman ML, Brunner N, Børresen-Dale AL, Gromov P, Helland Å, Kristensen VN, Gromova I.

Oncoimmunology. 2016 Oct 24;5(12):e1248015. doi: 10.1080/2162402X.2016.1248015. eCollection 2016.

14.

Characterization of the Tumor Secretome from Tumor Interstitial Fluid (TIF).

Gromov P, Gromova I.

Methods Mol Biol. 2016;1459:231-47. doi: 10.1007/978-1-4939-3804-9_16.

PMID:
27665563
15.

DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer.

Kanu N, Cerone MA, Goh G, Zalmas LP, Bartkova J, Dietzen M, McGranahan N, Rogers R, Law EK, Gromova I, Kschischo M, Walton MI, Rossanese OW, Bartek J, Harris RS, Venkatesan S, Swanton C.

Genome Biol. 2016 Sep 15;17(1):185. doi: 10.1186/s13059-016-1042-9.

16.

[Hygienic regulation of neonicotinoids derivative in the soil].

Rakitsky VN, Sinitskaya TA, Gromova IP, Klimova NN, Vafina DA.

Gig Sanit. 2016;95(11):1016-21. Russian.

PMID:
29431932
17.

Sensitive detection of lysosomal membrane permeabilization by lysosomal galectin puncta assay.

Aits S, Kricker J, Liu B, Ellegaard AM, Hämälistö S, Tvingsholm S, Corcelle-Termeau E, Høgh S, Farkas T, Holm Jonassen A, Gromova I, Mortensen M, Jäättelä M.

Autophagy. 2015;11(8):1408-24. doi: 10.1080/15548627.2015.1063871.

18.

Molecular and diagnostic features of apocrine breast lesions.

Gromov P, Espinoza JA, Gromova I.

Expert Rev Mol Diagn. 2015;15(8):1011-22. doi: 10.1586/14737159.2015.1057125. Epub 2015 Jun 25. Review.

PMID:
26111757
19.

High level PHGDH expression in breast is predominantly associated with keratin 5-positive cell lineage independently of malignancy.

Gromova I, Gromov P, Honma N, Kumar S, Rimm D, Talman ML, Wielenga VT, Moreira JM.

Mol Oncol. 2015 Oct;9(8):1636-54. doi: 10.1016/j.molonc.2015.05.003. Epub 2015 May 14.

20.

FABP7 and HMGCS2 are novel protein markers for apocrine differentiation categorizing apocrine carcinoma of the breast.

Gromov P, Espinoza JA, Talman ML, Honma N, Kroman N, Timmermans Wielenga V, Moreira JM, Gromova I.

PLoS One. 2014 Nov 12;9(11):e112024. doi: 10.1371/journal.pone.0112024. eCollection 2014.

21.

Decreased camptothecin sensitivity of the stem-cell-like fraction of Caco2 cells correlates with an altered phosphorylation pattern of topoisomerase I.

Roy A, Tesauro C, Frøhlich R, Hede MS, Nielsen MJ, Kjeldsen E, Bonven B, Stougaard M, Gromova I, Knudsen BR.

PLoS One. 2014 Jun 24;9(6):e99628. doi: 10.1371/journal.pone.0099628. eCollection 2014.

22.

Proteomic analysis of tissue samples in translational breast cancer research.

Gromov P, Moreira JM, Gromova I.

Expert Rev Proteomics. 2014 Jun;11(3):285-302. doi: 10.1586/14789450.2014.899469. Epub 2014 Mar 20. Review.

PMID:
24837673
23.

TIMP-1 increases expression and phosphorylation of proteins associated with drug resistance in breast cancer cells.

Hekmat O, Munk S, Fogh L, Yadav R, Francavilla C, Horn H, Würtz SØ, Schrohl AS, Damsgaard B, Rømer MU, Belling KC, Jensen NF, Gromova I, Bekker-Jensen DB, Moreira JM, Jensen LJ, Gupta R, Lademann U, Brünner N, Olsen JV, Stenvang J.

J Proteome Res. 2013 Sep 6;12(9):4136-51. doi: 10.1021/pr400457u. Epub 2013 Aug 21.

PMID:
23909892
24.

Tumor interstitial fluid - a treasure trove of cancer biomarkers.

Gromov P, Gromova I, Olsen CJ, Timmermans-Wielenga V, Talman ML, Serizawa RR, Moreira JM.

Biochim Biophys Acta. 2013 Nov;1834(11):2259-70. doi: 10.1016/j.bbapap.2013.01.013. Epub 2013 Feb 14. Review.

PMID:
23416532
25.

Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer.

Cabezón T, Gromova I, Gromov P, Serizawa R, Timmermans Wielenga V, Kroman N, Celis JE, Moreira JM.

Mol Cell Proteomics. 2013 Feb;12(2):381-94. doi: 10.1074/mcp.M112.019786. Epub 2012 Nov 20.

26.

Immunoexpression analysis and prognostic value of BLCAP in breast cancer.

Gromova I, Gromov P, Kroman N, Wielenga VT, Simon R, Sauter G, Moreira JM.

PLoS One. 2012;7(9):e45967. doi: 10.1371/journal.pone.0045967. Epub 2012 Sep 25.

27.

Express-evaluation of the psycho-physiological condition of Paralympic athletes.

Drozdovski A, Gromova I, Korotkov K, Shelkov O, Akinnagbe F.

Open Access J Sports Med. 2012 Dec 5;3:215-22. doi: 10.2147/OAJSM.S35888. eCollection 2012.

28.

Tissue proteomics of the human mammary gland: towards an abridged definition of the molecular phenotypes underlying epithelial normalcy.

Moreira JM, Cabezón T, Gromova I, Gromov P, Timmermans-Wielenga V, Machado I, Llombart-Bosch A, Kroman N, Rank F, Celis JE.

Mol Oncol. 2010 Dec;4(6):539-61. doi: 10.1016/j.molonc.2010.09.005. Epub 2010 Oct 8.

29.

Proteomic profiling of mammary carcinomas identifies C7orf24, a gamma-glutamyl cyclotransferase, as a potential cancer biomarker.

Gromov P, Gromova I, Friis E, Timmermans-Wielenga V, Rank F, Simon R, Sauter G, Moreira JM.

J Proteome Res. 2010 Aug 6;9(8):3941-53. doi: 10.1021/pr100160u.

PMID:
20527979
30.

HERC2 coordinates ubiquitin-dependent assembly of DNA repair factors on damaged chromosomes.

Bekker-Jensen S, Rendtlew Danielsen J, Fugger K, Gromova I, Nerstedt A, Lukas C, Bartek J, Lukas J, Mailand N.

Nat Cell Biol. 2010 Jan;12(1):80-6; sup pp 1-12. doi: 10.1038/ncb2008. Epub 2009 Dec 20. Erratum in: Nat Cell Biol. 2010 Apr;12(4):412. Lukas, Claudia [added].

PMID:
20023648
31.

Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast.

Gromov P, Gromova I, Bunkenborg J, Cabezon T, Moreira JM, Timmermans-Wielenga V, Roepstorff P, Rank F, Celis JE.

Mol Oncol. 2010 Feb;4(1):65-89. doi: 10.1016/j.molonc.2009.11.003. Epub 2009 Nov 23.

32.

Human BLCAP transcript: new editing events in normal and cancerous tissues.

Galeano F, Leroy A, Rossetti C, Gromova I, Gautier P, Keegan LP, Massimi L, Di Rocco C, O'Connell MA, Gallo A.

Int J Cancer. 2010 Jul 1;127(1):127-37. doi: 10.1002/ijc.25022.

33.

Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer.

Moreira JM, Ohlsson G, Gromov P, Simon R, Sauter G, Celis JE, Gromova I.

Mol Cell Proteomics. 2010 Jan;9(1):161-77. doi: 10.1074/mcp.M900294-MCP200. Epub 2009 Sep 25.

34.

Molecular characterization of apocrine carcinoma of the breast: validation of an apocrine protein signature in a well-defined cohort.

Celis JE, Cabezón T, Moreira JM, Gromov P, Gromova I, Timmermans-Wielenga V, Iwase T, Akiyama F, Honma N, Rank F.

Mol Oncol. 2009 Jun;3(3):220-37. doi: 10.1016/j.molonc.2009.01.005. Epub 2009 Feb 3.

35.

A single lysis solution for the analysis of tissue samples by different proteomic technologies.

Gromov P, Celis JE, Gromova I, Rank F, Timmermans-Wielenga V, Moreira JM.

Mol Oncol. 2008 Dec;2(4):368-79. doi: 10.1016/j.molonc.2008.09.003. Epub 2008 Oct 2.

36.

Omics-based profiling of carcinoma of the breast and matched regional lymph node metastasis.

Li J, Gromov P, Gromova I, Moreira JM, Timmermans-Wielenga V, Rank F, Wang K, Li S, Li H, Wiuf C, Yang H, Zhang X, Bolund L, Celis JE.

Proteomics. 2008 Dec;8(23-24):5038-52. doi: 10.1002/pmic.200800303.

PMID:
19003862
37.

15-prostaglandin dehydrogenase expression alone or in combination with ACSM1 defines a subgroup of the apocrine molecular subtype of breast carcinoma.

Celis JE, Gromov P, Cabezón T, Moreira JM, Friis E, Jirström K, Llombart-Bosch A, Timmermans-Wielenga V, Rank F, Gromova I.

Mol Cell Proteomics. 2008 Oct;7(10):1795-809. doi: 10.1074/mcp.R800011-MCP200. Epub 2008 Jul 16.

38.

Proteomic strategies in bladder cancer: From tissue to fluid and back.

Gromov P, Moreira JM, Gromova I, Celis JE.

Proteomics Clin Appl. 2008 Jul;2(7-8):974-88. doi: 10.1002/prca.200780163. Epub 2008 Jul 10.

PMID:
21136898
39.

A combined proteome and ultrastructural localization analysis of 14-3-3 proteins in transformed human amnion (AMA) cells: definition of a framework to study isoform-specific differences.

Moreira JM, Shen T, Ohlsson G, Gromov P, Gromova I, Celis JE.

Mol Cell Proteomics. 2008 Jul;7(7):1225-40. doi: 10.1074/mcp.M700439-MCP200. Epub 2008 Mar 31.

40.

IKAP localizes to membrane ruffles with filamin A and regulates actin cytoskeleton organization and cell migration.

Johansen LD, Naumanen T, Knudsen A, Westerlund N, Gromova I, Junttila M, Nielsen C, Bøttzauw T, Tolkovsky A, Westermarck J, Coffey ET, Jäättelä M, Kallunki T.

J Cell Sci. 2008 Mar 15;121(Pt 6):854-64. doi: 10.1242/jcs.013722. Epub 2008 Feb 26.

41.

Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: relationship between CK15+ progenitor/amplified cells and pre-malignant lesions and invasive disease.

Celis JE, Gromova I, Cabezón T, Gromov P, Shen T, Timmermans-Wielenga V, Rank F, Moreira JM.

Mol Oncol. 2007 Dec;1(3):321-49. doi: 10.1016/j.molonc.2007.09.004. Epub 2007 Sep 25.

42.

Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia.

Celis JE, Moreira JM, Gromova I, Cabezón T, Gromov P, Shen T, Timmermans V, Rank F.

Mol Oncol. 2007 Jun;1(1):97-119. doi: 10.1016/j.molonc.2007.02.005. Epub 2007 Mar 14.

43.

Human Xip1 (C2orf13) is a novel regulator of cellular responses to DNA strand breaks.

Bekker-Jensen S, Fugger K, Danielsen JR, Gromova I, Sehested M, Celis J, Bartek J, Lukas J, Mailand N.

J Biol Chem. 2007 Jul 6;282(27):19638-43. Epub 2007 May 16.

44.

Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia.

Celis JE, Gromova I, Gromov P, Moreira JM, Cabezón T, Friis E, Rank F.

FEBS Lett. 2006 May 22;580(12):2935-44. Epub 2006 Apr 12. Review.

45.

Apocrine cysts of the breast: biomarkers, origin, enlargement, and relation with cancer phenotype.

Celis JE, Gromov P, Moreira JM, Cabezón T, Friis E, Vejborg IM, Proess G, Rank F, Gromova I.

Mol Cell Proteomics. 2006 Mar;5(3):462-83. Epub 2005 Nov 28.

46.

Immediate and delayed effects of E-cadherin inhibition on gene regulation and cell motility in human epidermoid carcinoma cells.

Andersen H, Mejlvang J, Mahmood S, Gromova I, Gromov P, Lukanidin E, Kriajevska M, Mellon JK, Tulchinsky E.

Mol Cell Biol. 2005 Oct;25(20):9138-50.

47.

[An open-drop crystalloscopic procedure for studying serum in the toxicological-and-hygienic experiment].

Gromova IP.

Gig Sanit. 2005 Jan-Feb;(1):66-9. Russian. No abstract available.

PMID:
15751310
49.

Towards discovery-driven translational research in breast cancer.

Celis JE, Moreira JM, Gromova I, Cabezon T, Ralfkiaer U, Guldberg P, Straten PT, Mouridsen H, Friis E, Holm D, Rank F, Gromov P.

FEBS J. 2005 Jan;272(1):2-15. Review.

50.

Impact of proteomics on bladder cancer research.

Celis JE, Gromova I, Moreira JM, Cabezon T, Gromov P.

Pharmacogenomics. 2004 Jun;5(4):381-94. Review.

PMID:
15165174

Supplemental Content

Loading ...
Support Center